Obsessive–compulsive disorder

Aug 16, 2018

Biohaven Reports Positive Results From Double-Blind, Placebo-Controlled, Investigator Initiated, Proof Of Concept Trial Of BHV-0223 For Anxiety

Jul 13, 2018

Obsessive Compulsive Disorder Market in Europe 2018: Analysis & Forecasts (2017-2026)

Mar 29, 2018

Behavioral Disorders Drug Development Pipeline Review 2017 - Key Players Involved in Therapeutic Development for Autism, OCD and ADHD

Dec 21, 2017

Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder

Nov 28, 2017

Abide Therapeutics Reports Positive Topline Data from Phase 1b Study of ABX-1431 in Tourette Syndrome

Nov 20, 2017

Promentis Pharmaceuticals Commences Phase 1 Study for SXC-2023 Targeting Neuropsychiatric Disorders

Nov 06, 2017

Moleculera Labs Issued Key U.S. Patent Covering the Company's Diagnostic Panel for Infection-Induced Autoimmune Neuropsychiatric Disorders

Oct 24, 2017

Biohaven Receives FDA May Proceed Letter for Phase 2/3 Clinical Trial of Trigriluzole in Patients with Obsessive-Compulsive Disorder